UY27355A1 - Compuestos de espiropiperidina como ligandos para el receptor orl-1 - Google Patents
Compuestos de espiropiperidina como ligandos para el receptor orl-1Info
- Publication number
- UY27355A1 UY27355A1 UY27355A UY27355A UY27355A1 UY 27355 A1 UY27355 A1 UY 27355A1 UY 27355 A UY27355 A UY 27355A UY 27355 A UY27355 A UY 27355A UY 27355 A1 UY27355 A1 UY 27355A1
- Authority
- UY
- Uruguay
- Prior art keywords
- orl
- spyropiperidine
- ligandos
- receiver
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de fórmula: o una sal, pro fármaco o solvato del mismo, en la que todos los grupos R1 Y R2 son hidrógeno; A es un azaheteroanillo benzocondensado; W1- W2 es CH2- CH2; X1- X2 es CH2- CH2; y Z es metileno o carbonilo; o similar, es un ligando para el receptor ORL - 1 y es útil para tratar o prevenir el dolor, un trastorno del SNC o similares en mamíferos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30107901P | 2001-06-26 | 2001-06-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY27355A1 true UY27355A1 (es) | 2003-02-28 |
Family
ID=23161844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY27355A UY27355A1 (es) | 2001-06-26 | 2002-06-25 | Compuestos de espiropiperidina como ligandos para el receptor orl-1 |
Country Status (12)
Country | Link |
---|---|
US (3) | US20030078278A1 (es) |
EP (1) | EP1399432A1 (es) |
JP (1) | JP2005521630A (es) |
AP (1) | AP2002002562A0 (es) |
BR (1) | BR0211305A (es) |
CA (1) | CA2450550A1 (es) |
MX (1) | MXPA03011956A (es) |
PA (1) | PA8549101A1 (es) |
PE (1) | PE20030132A1 (es) |
SV (1) | SV2003001115A (es) |
UY (1) | UY27355A1 (es) |
WO (1) | WO2003000677A1 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0307268A (pt) * | 2002-01-28 | 2004-12-14 | Pfizer | Compostos de espiropiperidina n-substituìda como ligantes para o receptor orl-1 |
US7566728B2 (en) * | 2002-03-29 | 2009-07-28 | Mitsubishi Tanabe Pharma Corporation | Remedy for sleep disturbance |
CN100402529C (zh) * | 2002-09-09 | 2008-07-16 | 詹森药业有限公司 | 用于治疗orl-1受体介导疾病的羟基烷基取代的1,3,8-三氮杂螺[4,5]癸-4-酮衍生物 |
US7247725B2 (en) * | 2002-10-30 | 2007-07-24 | Merck & Co., Inc. | Gamma-aminoamide modulators of chemokine receptor activity |
MXPA05010724A (es) | 2003-04-04 | 2005-12-15 | Merck & Co Inc | Derivados de las espiropiperidinas aciladas como agonistas del receptor de la melanocortina-4. |
WO2005016913A1 (en) * | 2003-08-19 | 2005-02-24 | Pfizer Japan, Inc. | Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders |
EP1732893A2 (en) * | 2004-03-29 | 2006-12-20 | Pfizer Japan, Inc. | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist |
WO2005117862A1 (en) * | 2004-06-03 | 2005-12-15 | Pfizer Limited, | Treatment of urinary conditions including incontinence |
AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
AR056968A1 (es) | 2005-04-11 | 2007-11-07 | Xenon Pharmaceuticals Inc | Compuestos espiro-oxindol y composiciones farmacéuticas |
EP1890696A4 (en) * | 2005-06-02 | 2010-05-05 | Janssen Pharmaceutica Nv | Suitable as new ORL-1 receptor modulators are 3-pyrolytic indolyl derivatives |
EP1893610A2 (en) * | 2005-06-17 | 2008-03-05 | Pfizer, Inc. | Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as orl1-receptor antagonists |
MX2007016215A (es) * | 2005-06-17 | 2008-03-07 | Pfizer | Compuestos del acido alfa-(aril-o heteroaril-metil)-beta-piperidin opropanoico como antagonistas del receptor orl1. |
WO2007047496A2 (en) | 2005-10-18 | 2007-04-26 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
US20080015214A1 (en) * | 2005-10-24 | 2008-01-17 | Bignan Gilles C | 3-piperidin-4-yl-indole orl-1 receptor modulators |
WO2007057775A1 (en) * | 2005-11-21 | 2007-05-24 | Pfizer Limited | Spiropiperidine derivatives |
GB0608452D0 (en) * | 2006-04-27 | 2006-06-07 | Glaxo Group Ltd | Novel compounds |
TW200833695A (en) | 2006-10-12 | 2008-08-16 | Xenon Pharmaceuticals Inc | Use of spiro-oxindole compounds as therapeutic agents |
WO2008056687A1 (fr) * | 2006-11-09 | 2008-05-15 | Daiichi Sankyo Company, Limited | Nouveau dérivé de spiropipéridine |
WO2008067167A1 (en) * | 2006-11-28 | 2008-06-05 | Janssen Pharmaceutica N.V. | Salts of 3-(3-amino-2-(r)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one |
WO2008124209A1 (en) * | 2007-04-09 | 2008-10-16 | Janssen Pharmaceutica, N.V. | 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression |
NZ600238A (en) | 2008-06-19 | 2014-04-30 | Takeda Pharmaceutical | Heterocyclic compound and use thereof |
US8101647B2 (en) | 2008-10-17 | 2012-01-24 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
RU2011119626A (ru) | 2008-10-17 | 2012-11-27 | Ксенон Фармасьютикалз Инк. | Спирооксиндольные соединения и их применение в качестве терапевтичеких средств |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
EP2488531B1 (en) | 2009-10-14 | 2014-03-26 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
WO2011106729A2 (en) | 2010-02-26 | 2011-09-01 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
WO2014146111A2 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Analgesic compounds and methods of use |
WO2016127068A1 (en) | 2015-02-05 | 2016-08-11 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
CN112940075B (zh) * | 2021-01-07 | 2023-03-31 | 渤海大学 | 一种乙酰胆碱酯酶抑制肽及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3654287A (en) * | 1970-08-26 | 1972-04-04 | Mead Johnson & Co | Spiroindanylpiperidines |
US3962259A (en) * | 1973-12-12 | 1976-06-08 | American Hoechst Corporation | 1,3-Dihydrospiro[isobenzofuran]s and derivatives thereof |
GB1435054A (en) * | 1974-02-04 | 1976-05-12 | Ici Ltd | Dihydroanthracene derivatives |
NZ243065A (en) * | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
WO1995028389A1 (fr) * | 1994-04-15 | 1995-10-26 | Yamanouchi Pharmaceutical Co., Ltd. | Compose spiro et composition medicinale issue de ce compose |
US5962462A (en) * | 1996-12-13 | 1999-10-05 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
KR20010020172A (ko) * | 1997-05-30 | 2001-03-15 | 나가사까 겐지로 | 2-옥소이미다졸 유도체 |
US6166209A (en) * | 1997-12-11 | 2000-12-26 | Hoffmann-La Roche Inc. | Piperidine derivatives |
ID29137A (id) * | 1998-07-27 | 2001-08-02 | Schering Corp | Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1 |
AU2001288110A1 (en) * | 2000-09-27 | 2002-04-08 | Takeda Chemical Industries Ltd. | Spiro compounds |
-
2002
- 2002-03-06 US US10/092,040 patent/US20030078278A1/en not_active Abandoned
- 2002-05-22 US US10/153,310 patent/US20030078279A1/en not_active Abandoned
- 2002-06-17 MX MXPA03011956A patent/MXPA03011956A/es unknown
- 2002-06-17 BR BR0211305-8A patent/BR0211305A/pt not_active IP Right Cessation
- 2002-06-17 JP JP2003507081A patent/JP2005521630A/ja active Pending
- 2002-06-17 WO PCT/IB2002/002272 patent/WO2003000677A1/en not_active Application Discontinuation
- 2002-06-17 EP EP02730637A patent/EP1399432A1/en not_active Withdrawn
- 2002-06-17 CA CA002450550A patent/CA2450550A1/en not_active Abandoned
- 2002-06-17 US US10/481,210 patent/US20050038060A1/en not_active Abandoned
- 2002-06-20 AP APAP/P/2002/002562A patent/AP2002002562A0/en unknown
- 2002-06-24 PE PE2002000550A patent/PE20030132A1/es not_active Application Discontinuation
- 2002-06-25 UY UY27355A patent/UY27355A1/es not_active Application Discontinuation
- 2002-06-25 SV SV2002001115A patent/SV2003001115A/es unknown
- 2002-06-26 PA PA20028549101A patent/PA8549101A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
SV2003001115A (es) | 2003-03-18 |
JP2005521630A (ja) | 2005-07-21 |
PA8549101A1 (es) | 2003-01-24 |
EP1399432A1 (en) | 2004-03-24 |
CA2450550A1 (en) | 2003-01-03 |
US20050038060A1 (en) | 2005-02-17 |
US20030078278A1 (en) | 2003-04-24 |
MXPA03011956A (es) | 2004-03-26 |
US20030078279A1 (en) | 2003-04-24 |
AP2002002562A0 (en) | 2002-06-30 |
WO2003000677A1 (en) | 2003-01-03 |
PE20030132A1 (es) | 2003-02-28 |
BR0211305A (pt) | 2004-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY27355A1 (es) | Compuestos de espiropiperidina como ligandos para el receptor orl-1 | |
IL155702A0 (en) | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5-ht2 receptor | |
PA8468401A1 (es) | Compuestos para el tratamiento de la isquemia | |
ATE487477T1 (de) | Nicht-sedierender a-2 agonist 1-(2,3-dimethyl- phenyl)-ethyl-1, 3-dihydro-imizadol-2-thion | |
CY1111493T1 (el) | Παραγωγα πυραζολιου ως τροποποιητες πρωτεϊνοκινασης | |
AR018705A1 (es) | Procedimientos e intermedios para preparar compuestos anticancerosos. | |
CY1106679T1 (el) | Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα | |
GT199900067A (es) | Nuevas 4-fenilpiperidinas para el tratamiento dedermatosis prurìtica. | |
PA8480101A1 (es) | Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos | |
DE602004016127D1 (de) | Antagonisten der opioidrezeptoren | |
ES2058265T3 (es) | Piperidinas antagonistas de opiaceos. | |
YU39803A (sh) | Jedinjenja piperazinilpirazina kao agonisti ili antagonisti serotonin 5ht-2-receptora | |
ECSP045077A (es) | Derivados del 3-azabiciclico[3.1.0]hexano como antagonistas del receptor de opioides | |
AR027539A1 (es) | Nuevos derivados de 1,3-dihidro-2h-indol-2-ona, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen | |
MX9204094A (es) | Derivados de fenilalquilo, medicamentos que contienen estos compuestos y procedimiento para su preparacion. | |
AR018162A1 (es) | Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica | |
AR028743A1 (es) | DERIVADOS DE N-TRIAZOLILMETIL-PIPERAZINA CON ACCIoN ANTAGONISTA DE RECEPTORES DE NEUROQUININA | |
PA8486701A1 (es) | Antagonistas de 5ht1 para terapia antidepresiva | |
ES2196069T3 (es) | Derivados morfinoides condensados con heterociclos. | |
AR028947A1 (es) | Compuestos novedosos | |
ES2195089T3 (es) | Benzotiofenos amorfos, procedimientos de preparacion y uso. | |
UY27770A1 (es) | Imidazolinilmetil aralquilsulfonamidas | |
FR2707990B1 (fr) | Nouvelles nitrones utilisables pour le piégeage des radicaux libres. | |
MX9306178A (es) | Bencimidazoles medicamentos que contienen estos compuestos yprocedimientos para su preparacion. | |
ES2173675T3 (es) | Procedimiento de preparacion de carboxamido-4-azaesteroides. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20141203 |